Computational Insights into the Polypharmacological Landscape of BCR-ABL Inhibitors: Emphasis on Imatinib and Nilotinib
<b>Background:</b> BCR-ABL inhibitors such as imatinib and nilotinib exhibit multi-kinase activity that extends beyond oncology, offering significant potential for drug repurposing. <b>Objectives:</b> This study aims to systematically evaluate and prioritize the repurposing p...
Saved in:
| Main Authors: | Rima Hajjo, Dima A. Sabbah, Raghad Alhaded, Aye Alquabe’h, Sanaa K. Bardaweel |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/7/936 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre: A retrospective observational study
by: Ana Maria Meireles, et al.
Published: (2025-07-01) -
Predicting Binding Affinity of Some Imatinib Derivatives as BCR-ABL Tyrosine Kinase Inhibitors Based on Monte Carlo Optimization
by: Shahram Lotfi, et al.
Published: (2024-09-01) -
A network-based approach to overcome BCR::ABL1-independent resistance in chronic myeloid leukemia
by: Valeria Bica, et al.
Published: (2025-04-01) -
Chronic Myeloid Leukemia Patient Registry in the Russian Federation: From Observational Studies to the Efficacy Evaluation in Clinical Practice
by: AG Turkina, et al.
Published: (2017-07-01) -
Somatically mutated ABL1 is an actionable and essential NSCLC survival gene
by: Ewelina Testoni, et al.
Published: (2016-01-01)